MRI-based methods to detect placental and fetal brain abnormalities in utero

Journal of Reproductive Immunology

Volumn 114, Issue , 2016, Pages 86-91

  Girardi, Guillermina ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Complement activation; Fetal brain development; Inflammation; MRI; Placental insufficiency

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; NANOPARTICLE;

ADVERSE OUTCOME; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN DAMAGE; BRAIN DEVELOPMENT; BRAIN METABOLISM; COMPLEMENT ACTIVATION; FETAL BRAIN; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLACENTA INSUFFICIENCY; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ABNORMALITIES; ANIMAL; BRAIN; DIAGNOSTIC IMAGING; FEMALE; FETUS; MOUSE; PLACENTA; PROCEDURES;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; BRAIN; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; FETUS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; NANOPARTICLES; PLACENTA; PLACENTAL INSUFFICIENCY; PREGNANCY;

EID: 84945533200     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2015.05.008     Document Type: Article

References (35)

1. Brighina E., Bresolin N., Pardi G., Rango M. Human fetal brain chemistry as detected by proton magnetic resonance spectroscopy. Pediatr. Neurol. 2009, 40:327-342.
2. Bulas D., Egloff A. Benefits & risks of MRI in pregnancy. Semin. Perinatol. 2013, 3:301-304.
3. Cohen D., Buurma A., Goemaere N.N., Girardi G., le Cessie S., Scherjon S., Bloemenkamp K.W., de Heer E., Bruijn J.A., Bajema I.M. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J. Pathol. 2011, 225:502-511.
4. Counsell S.J., Rutherford M.A., Cowan F.M., Edwards A.D. Magnetic resonance imaging of preterm brain injury. Arch. Dis. Child. Fetal Neonatal. Ed. 2003, 88:F269-F274.
5. Denison F.C., Semple S.I., Stock S.J., Walker J., Marshall I., Norman J.E. Novel use of proton magnetic resonance spectroscopy (1H MRS) to non-invasively assess placental metabolism. PLOS ONE 2012, 7(8):e42926. 10.1371/journal.pone.0042926.
6. Denny K.J., Woodruff T.M., Taylor S.M., Callaway L.K. Complement in pregnancy: a delicate balance. Am. J. Reprod. Immunol. 2013, 69:3-11.
7. 3 elicits diameter-dependent effects during exposure to an in vitro model of the human placenta. Cell Biol. Toxicol. 2014, 30:31-53.
8. Harris E.N. Syndrome of the black swan. Br. J. Rheumatol. 1987, 26:324-326.
9. Girard N., Gouny S.C., Viola A., Le Fur Y., Viout P., Chaumoitre K., D'Ercole C., Gire C., Figarella-Branger D., Cozzone P.J. Assessment of normal fetal brain maturation in utero by proton magnetic resonance spectroscopy. Magn. Reson. Med. 2006, 56:768-775.
10. Girard N., Fogliarini C., Viola A., Confort-Gouny S., Le Fur Y., Viout P., Chapon F., Levrier O., Cozzone P. MRS of normal and impaired fetal brain development. Eur. J. Radiol. 2006, 25:217-225.
11. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., Hollmann T.J., Casali P., Caroll M.C., Wetsel R.A., Lambris J.D., Holers V.M., Salmon J.E. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 2003, 112:1644-1654.
12. Girardi G., Prohászka Z., Bulla R., Tedesco F., Scherjon S. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol. Immunol. 2011, 48:1621-1630.
13. Girardi G., Fraser J., Lennen R., Vontell R., Jansen M., Hutchison G. Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO) - conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development. Mol. Psychiatry 2014, 10.1038/mp.2014.110.
14. Gonzalez J.M., Pedroni S.M., Girardi G. Statins prevent cervical remodeling, myometrial contractions and preterm labor through a mechanism that involves hemoxygenase-1 and complement inhibition. Mol. Hum. Reprod. 2014, 20:579-589.
15. Heerschap A., van den Berg P.P. Proton magnetic resonance spectroscopy of human fetal brain. Am. J. Obstet. Gynecol. 1994, 170:1150-1151.
16. Keelan J.A. Nanotoxicology: nanoparticles versus the placenta. Nat. Nanotechnol. 2011, 6:263-264.
17. Keswani S.C., Chauhan N. Antiphospholipid syndrome. J. R. Soc. Med. 2002, 95:336-342.
18. Kondo H., Saito K., Grasso J.P., Aisen P. Iron metabolism in the erythrophago cytosing Kupffer cell. Hepatology 1988, 8:32-38.
19. Kulvietis V., Zalgeviciene V., Didziapetriene J., Rotomskis R. Transport of nanoparticles through the placental barrier. Tohoku J. Exp. Med. 2011, 225:225-234.
20. Lin C., Cai S., Feng J. Positive contrast imaging of SPIO nanoparticles. J. Nanomater. 2012, Article ID 734842. 10.1155/2012/734842.
21. Lynch A.M., Gibbs R.S., Murphy J.R., Byers T., Neville M.C. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am. J. Obstet. Gynecol. 2008, 199:354-358.
22. Patenaude Y., Pugash D., Lim K., Morin L., Diagnostic Imaging Committee The use of magnetic resonance imaging in the obstetric patient. J. Obstet. Gynaecol. Can. 2014, 36:349-363.
23. Pedroni S.M., Gonzalez J.M., Wade J., Jansen M.A., Serio A., Marshall I., Lennen R.J., Girardi G. Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim. Biophys. Acta 2014, 1842:107-115.
24. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 2007, 110:2423-2431.
25. Redecha P., Franzke C.W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J. Clin. Invest. 2008, 118:3453-3461.
26. Romero R., Espinoza J., Gonçalves L.F., Kusanovic J.P., Friel L.A., Nien J.K. Inflammation in preterm and term labour and delivery. Semin. Fetal. Neonatal. Med. 2006, 11:317-326.
27. Romero R., Espinoza J., Kusanovic J.P., Gotsch F., Hassan S., Erez O., Chaiworapongsa T., Mazor M. The preterm parturition syndrome. Br. J. Obstet. Gynecol. 2006, 113:17-42.
28. Sargsyan S.A., Serkova N.J., Renner B., Hasebroock K.M., Larsen B., Stoldt C., McFann K., Pickering M.C., Thurman J.M. Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int. 2012, 81:152-159.
29. Serkova N.J., Renner B., Larsen B.A., Stoldt C.R., Hasebroock K.M., Bradshaw-Pierce E.L., Holers V.M., Thurman J.M. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 2010, 255:517-526.
30. Smith F.W., Adam A.H., Phillips W.D. NMR imaging in pregnancy. Lancet 1983, 1:61.
31. Stone S., Pijnenborg R., Vercruysse L., Poston R., Khamashta M.A., Hunt B.J., Poston L. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006, 27:457-467.
32. Story L., Damodaram M.S., Allsop J.M., McGuinness A., Patel A., Wylezinska M., Hagberg H., Kumar S., Rutherford M.A. Brain metabolism in fetal intrauterine growth restriction: a proton magnetic resonance spectroscopy study. Am. J. Obstet. Gynecol. 2011, 205:483-489.
33. Thurman J.M., Serkova N. Nano-sized contrast agents to non-invasively detect renal inflammation by MRI. Adv. Chronic Kidney Dis. 2013, 20:488-499.
34. Wang Y.X. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg. 2011, 1:35-40.
35. Wang Z.J., igneron D.V., Miller S.P., Mukherjee P., Charlton N.N., Lu Y., Barkovich A.J. Brain metabolite levels assessed by lactate-edited MR spectroscopy in premature neonates with and without pentobarbital sedation. AJNR Am. J. Neuroradiol. 2008, 29:798-801.